Infectious Disease
Ebola Virus Disease
0
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Ebola Virus Disease is an early-stage landscape with 0 programs across 2 companies. The most active players are Jazz Pharmaceuticals, Regeneron.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
8
clinical trials
Completed3 · 38%
Unknown status2 · 25%
Terminated1 · 13%
Withdrawn1 · 13%
Available1 · 13%
Clinical Trials
Trial Activity
8 trials
A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine
Completed·Jiangsu Province Centers for Disease Control and Prevention·Phase 2·NCT02575456·500 enrolled
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT03719586·681 enrolled
Efficacy of Favipiravir Against Severe Ebola Virus Disease
Completed·—·Phase 2·NCT02662855·77 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)